A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp
This Expanded Access Program aims to:
1. Provide access to tebentafusp for mUM patients.
2. Provide access to tebentafusp for patients, who were on the control arm of the
randomized controlled Phase II trial (IMCgp100-202) and were unable to crossover during
the specified window.
3. Ensure that patients, who are benefiting from tebentafusp treatment while participating
in an ongoing Immunocore sponsored clinical study (e.g., IMCgp100-102 or IMCgp100-201),
may continue tebentafusp treatment on this Programme once the ongoing trial has met all
of its key primary and secondary objectives.